Christina Walker: Novel Biomarkers for PCOS and DOR
Christina Walker, Program Director of CLS Event and Publication, shared on LinkedIn։
”Novel Biomarkers for PCOS and DOR: Moving Toward Precision Fertility Care
Research into novel biomarkers for Polycystic Ovary Syndrome (PCOS) and Diminished Ovarian Reserve (DOR) is opening new avenues for understanding reproductive health, diagnosis, and individualized fertility care.
PCOS: Beyond Conventional Markers
PCOS is highly heterogeneous, making diagnosis and risk assessment challenging.
Recent research is exploring combinations of:
- MicroRNAs
- Metabolomic Signatures
- Hormonal and Metabolic Biomarkers
DOR: Looking Beyond AMH
Emerging research is therefore examining the follicular microenvironment through:
- Proteomics
- Inflammatory markers
- Follicular-fluid biomarkers
- Metabolomics
- Molecular signatures associated with follicular function
A 2026 study using targeted proteomics identified a four-protein follicular-fluid signature involving ADA, VEGFA, 4E-BP1, and MMP-1 that showed promising diagnostic performance for DOR in its study cohort.
Where Could Biomarker Research Take Fertility Medicine?
The bigger question is not simply ‘Which biomarker is best?’
It is:
Can multiple biological signals be combined to create a more complete picture of an individual patient’s reproductive health?
Future research may explore:
- Earlier identification of reproductive risks
- Better characterization of PCOS phenotypes
- Improved assessment of ovarian reserve
- Molecular profiling of the follicular environment
- Prediction of treatment response
- More individualized fertility strategies
- Integration of biomarkers with AI and clinical data
Bring the Biomarker Conversation to GFWH2026
The 12th Global Summit on Gynecology, Fertility and Women’s Health provides a platform for researchers and healthcare professionals working across PCOS, ovarian reserve, reproductive endocrinology, fertility research, IVF, embryology, and precision medicine.
November 23–24, 2026
Grand Mercure Bangkok Atrium, Bangkok, Thailand
Which emerging biomarker or biomarker platform do you think deserves greater attention in PCOS and ovarian reserve research?”
Other articles featuring Christina Walker on Fertility News.
-
Nov 13, 2026, 17:25From Contraception to Fertility Treatment, Reproductive Health Care Is a Human Right – ASRM
-
Nov 13, 2026, 17:15Discussing Planned Committee Projects and Much More with the ESGO Council
-
Nov 13, 2026, 17:08Don’t Forget the Male: An Interview with Francesco Lotti – ESHRE
-
Nov 13, 2026, 16:57Amos Grünebaum: 8 Tools, 1 Pregnancy, All Free
-
Nov 13, 2026, 16:51Amy Sparks: Humbled and Honored to Serve as President of the ASRM
-
Nov 13, 2026, 16:47New Preeclampsia Awareness Report Reveals Gaps in Preeclampsia Awareness – Preeclampsia Foundation
-
Nov 13, 2026, 16:40Ritik Shukla: Honoured to Welcome Suriyadeo Tripathi as a Keynote Speaker at GFWH 2026
-
Nov 13, 2026, 16:33RBMO Study Uses AI to Assess Shortened Embryo Warming Protocols
-
Nov 13, 2026, 16:26Joni Hetfield: How Kindbody Came Apart